KNKimberly Danae Cauley Narain

Kimberly Danae Cauley Narain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kimberly Danae Cauley Narain has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • Carol M. Mangione

    Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA

    5 shared publications
  • O. Kenrik Duru

    Division of General Internal Medicine and Health Services Research (GIM/HSR), Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA

    4 shared publications
  • Frederick J. Zimmerman

    Department of Health Policy and Management, Center for Health Advancement, UCLA, Los Angeles, CA, USA

    3 shared publications
  • Gerardo Moreno

    Department of Family Medicine, David Geffen School of Medicine, University of California, Los Angeles

    3 shared publications
  • Bevanne Bean-Mayberry

    Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA

    2 shared publications
  • Carol Mangione

    Division of General Internal Medicine and Health Services Research, Department of Medicine, University of California, Los Angeles, CA, USA

    2 shared publications

Latest Publications

  • Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1–Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop

    by Lesley H. Curtis, David Arterburn, Sengwee Toh, Jingchuan Guo, Miguel A. Hernán, Esti Iturralde, Ania Jastreboff, Kristina H. Lewis, Jennifer L. Lund, Matthew L. Maciejewski, et al.

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have reshaped the clinical approach to managing obesity and type 2 diabetes. As approved indications have expanded, use of GLP-1RAs has increased rapidly in the United States. Although randomized trials demonstrate strong efficacy, many questions remain about their optimal use in clinical practice. Real-world data (RWD) from electronic health records, registries, insurance claims, and other sources offer a promising avenue to address these questions. However, concerns about data quality, selection bias, and incomplete ascertainment of medication use and outcomes pose significant challenges to the validity of the resulting evidence. In May 2025, the National Institute of Diabetes and Digestive and Kidney Diseases convened experts from regulatory agencies, payer organizations, and academia to explore these challenges. This second of 2 synopsis articles on the workshop summarizes the discussion around the strengths and limitations of various RWD sources and methodological approaches to strengthen causal inference and generalizability. Presenters highlighted pragmatic clinical trials and target trial emulation as strategies to generate stronger real-world evidence (RWE) that is relevant to both clinical practice and policy. The workshop underscored that careful attention to study design, data limitations, and analytic approach is essential to yield RWE that informs clinicians, patients, payers, and policymakers.


  • Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1–Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop

    by David Arterburn, Lesley H. Curtis, Sengwee Toh, Marie C. Bradley, David D’ALessio, Noelia Duchovny, David Hines, Kimberly Narain, Anand Parekh, Asheley Skinner, et al.

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity and diabetes management, with rapidly expanding indications and use among U.S. adults. Despite their promise, key questions remain about optimal treatment pathways, long-term safety, effectiveness across diverse populations, adherence, and economic impact. Real-world evidence (RWE) derived from electronic health records, claims, and other data sources could address these gaps, but unique challenges complicate its use, such as inconsistent insurance coverage, high discontinuation rates, medication shortages, compounded formulations, and off-label prescribing. To explore these issues, the National Institute of Diabetes and Digestive and Kidney Diseases convened a workshop in May 2025 with experts from regulatory agencies, guideline committees, payers, and academia. Discussions focused on identifying knowledge gaps in GLP-1RA use, evaluating how RWE informs practice, assessing limitations of real-world data, and strategies to reduce bias in RWE. Presentations emphasized RWE's potential to complement randomized trials by capturing rare adverse events, long-term outcomes, and effectiveness in routine care. However, persistent challenges include data reliability, confounding, and incomplete capture of medication use and outcomes, particularly in pediatric and underserved populations. Coverage decisions remain heterogeneous across Medicare, Medicaid, and private payers and across time, underscoring the need for rigorous cost-benefit analyses. The workshop concluded that robust RWE is essential for developing value-based coverage policies and optimizing GLP-1RA use. Continued investment in high-quality data infrastructure and analytic methods will be critical to inform regulatory, clinical, and economic decisions as utilization expands.


  • Open Access

    A cross-sectional analysis of the association between self-employment, racial and ethnic minority status, sex and cardiovascular disease risk factors among a nationally representative sample

    by Kimberly Narain, Daniela Markovic, José J. Escarce

    Background: There is a body of evidence that suggest risk factors for cardiovascular disease (CVD) may be linked with self-employment status. Work context varies across race, ethnicity and sex. The objective is to examine the association of self-employment status and CVD risk factors across racial and ethnic minority status as well as sex. Methods: For this observational study, National Health and Nutrition Examination Survey (NHANES) data (1999–2018), a cross-sectional study design, and stratified logistic regression models were used to explore the association between self-employment status (a dichotomous variable) and CVD risk factors (dichotomized measures of elevated cholesterol, hypertension, glucose intolerance, obesity, poor diet, physical inactivity, smoking, binge drinking, sub-optimal sleep duration and poor mental health) across combined racial and ethnic minority status and sex groups, among working, non-pregnant adults(ages 30–62). Statistical models controlled for age, education, marital status, household poverty-to-income ratio, and the number of months working at current job. The coefficient estimates were expressed as predictive margins. Results: The study sample was comprised of 19,395 working adults. Among non-minority women, self-employment was negatively associated with obesity (% diff = -7.4%; p = 0.008), physical inactivity % diff = -7.0%; p = 0.017), and poor sleep duration (% diff = -9.4%; p = 0.004). Among minority women, self-employment was negatively associated with poor diet (% diff = -6.7%; p = 0.024), physical inactivity (% diff =-7.3%; p = 0.013) and poor sleep duration (% diff = -8.1%; p = 0.017). Among non-minority men, self-employment was negatively associated with poor diet (% diff = -6.5%; p = 0.008) and hypertension (% diff = -5.7%; p = 0.013). Conclusions: This study suggests that there may be a relationship between work context and CVD risk factors that varies across race, ethnicity and sex; however, further research is needed to characterize this relationship. Specifically, exploring how autonomy, flexibility, social support and discrimination exposure varies across self-employment status in diverse demographic groups may be important for illuminating the relationship between work and cardiovascular health.


  • Open Access

    Exploring Racial and Ethnic Differences in Utilization of Medications for Obesity Management in a Nationally Representative Survey

    by Kimberly Narain, Christopher Scannell

    Background: The burden of obesity falls disproportionately on some racial and ethnic minority groups. Objective: To assess for racial and ethnic differences in the utilization of obesity-management medications among clinically eligible individuals. Design: Medical Expenditure Panel Survey (2011–2016, 2018 and 2020) data and a cross-sectional study design was used to assess for racial and ethnic differences in obesity-management medication utilization. Descriptive statistics and multivariable logistic regression models were used to identify the association of race and ethnicity with obesity-management medication utilization. Adjusted models controlled for demographics, socioeconomic status, obesity class, diabetes status, number of chronic conditions, insurance status, and geographic region. Participants: Adults with a BMI ≥ 30 kg/m 2 and individuals with a BMI ≥ 27 kg/m 2 with ≥ 1 weight-related condition. Main Measures: The primary outcome measure was utilization of an FDA-approved medication for obesity-management during the study period. The primary independent predictor was race and ethnicity. Separate indicator variables were created for each racial and ethnic group (Non-Hispanic Asian, Non-Hispanic Black, Hispanic, and Non-Hispanic White (reference group)). Key Results: In adjusted analyses, Asian (aOR, 0.36; 95% CI, 0.16 to 0.77; P < 0.01), Black (aOR, 0.51; 95% CI, 0.39 to 0.68; P < 0.001) and Hispanic individuals (aOR, 0.70; 95% CI, 0.49 to 0.98; P = 0.04) had significantly lower odds of utilizing obesity-management medications compared to White individuals. Conclusions: The results of this study suggest that there are racial and ethnic disparities in the use of obesity-management medications.


  • Open Access

    Exploring the Relationship Between Medication Adherence and Diabetes Disparities among Hispanic Patients in a Large Health System

    by Kimberly Danae Cauley Narain, Ayan Patel, Samuel Skootsky, Carol M. Mangione

    Background: Sub-optimal HbA1c control is a driver of disparities in diabetes outcomes among Hispanic patients. Differences in medication adherence may underlie racial/ethnic differences in HbA1c level. Objective: To examine the relationship between medication adherence and disparities in HbA1c level among Hispanic patients, relative to other racial/ethnic groups, obtaining care in the University of California Health System (UC Health). Design: This study used clinical, administrative, and prescription dispensing data (January–December 2021) derived from the electronic health records of 5 Academic Medical Centers in UC Health, and linear regression models (LRMs) to conduct a cross-sectional analysis of the association between medication adherence, race/ethnicity, and HbA1c level. Adjusted LRMs were run with and without the measure of medication adherence to assess this relationship. Participants: Patients with a UC Health primary care physician (PCP), with ≥ 1 PCP visit within the last 3 years, ages 18–75, reporting Asian, Hispanic, or White race/ethnicity, and who had ≥ 2 encounters with an ICD diagnosis of diabetes or had a prescription for a diabetes medication within the last 2 years, as of 12/31/21 (N = 27, 542; Asian = 6253, Hispanic = 7216, White = 14,073). Main Measures: Our measure of medication adherence was the proportion of days covered (PDC) for diabetes medications in 2021. Our outcome was the most recent HbA1c value. Key Results: In the LRM excluding the PDC, Hispanic ethnicity was positively associated with HbA1c level (β = 0.31, p = < 0.001). In the LRM model including PDC, PDC was negatively associated with HbA1c level (β = − 0.18, p = < 0.001). However, the positive relationship between Hispanic ethnicity and HbA1c level did not change (β = 0.31, p = < 0.001). Conclusions: The findings of this study suggest that the relationship between Hispanic ethnicity, HbA1c level, and factors outside of medication adherence should be explored among primary care patients receiving care in Academic Medical Centers.


  • Pharmacist-Led Diabetes Control Intervention and Health Outcomes in Hispanic Patients With Diabetes

    by Kimberly Danae Cauley Narain, Gerardo Moreno, Douglas S. Bell, Lillian Chen, Chi-Hong Tseng, Robert W. Follett, Samuel Skootsky, Carol M. Mangione

    Importance: Among patients with type 2 diabetes (T2D), Hispanic individuals are more likely than non-Hispanic White individuals to develop diabetes-related complications.Objective: To examine the association of a pharmacist-led intervention (UCMyRx) with hemoglobin A1c(HbA1c) and systolic blood pressure (SBP) among Hispanic patients with T2D.Design, Setting, and Participants: This quality improvement study used electronic health record data and a difference-in-differences study design to evaluate the association of UCMyRx exposure with changes in HbA1cconcentration and SBP among Hispanic patients with T2D, relative to usual care, at University of California, Los Angeles primary care clinics between February and April of 2023. The study population included patients with anInternational Classification of Diseases, Ninth Revision/International Statistical Classification of Diseases and Related Health Problems, Tenth Revisiondiagnosis of T2D, self-reporting Hispanic ethnicity, age 18 years or older, with 1 or more visits with a UCMyRx pharmacist (treatment) or 2 or more visits, 2 or more years apart, during the study window (comparison). Additionally, patients had to have the following observations during the study window (March 2, 2013-December 31, 2018): (1) a HbA1c8% or higher, anywhere between 365 days before and 14 days after the index date (date of the first UCMyRx visit or a randomly generated index date) and a follow-up HbA1cmeasure within 120 to 365 days after the index date (n = 396) and/or (2) a SBP 140 mm Hg or higher between 365 days before and 14 days after the index date, and a follow-up SBP measure within 120 to 450 days after the index date (n = 795).Exposure: Pharmacists review laboratory results/vital signs, perform medication reconciliation, and develop personally tailored interventions to address adherence barriers and increase guideline-concordant care.Main Outcomes and Measures: Pre– to post–index date changes in HbA1cand SBP.Results: Of the 931 unique patients with T2D analyzed, the mean (SD) age was 64 (14.1) years, and 552 (59.3%) were female. In adjusted analyses, having 1 or more UCMyRx visits was associated with a reduction in HbA1cconcentration (β = −0.46%; 95% CI, −0.84% to −0.07%) but no change in SBP (β = −1.71 mm Hg; 95% CI, −4.00 to 0.58 mm Hg).Conclusions and Relevance: In this quality improvement study of UCMyRx among Hispanic patients with T2D, a negative association was observed between UCMyRx exposure and HbA1cconcentration but not SBP. Pharmacist-led intervention may be a strategy for improving outcomes among Hispanic patients with T2D.


  • Open Access

    The Diabetes Health Plan and Healthcare Utilization Among Beneficiaries with Low Incomes

    by Kimberly Danae Cauley Narain, Norman Turk, O. Kenrik Duru, Tannaz Moin, Carol M. Mangione

    Background: The socioeconomic status (SES) gradient in hospital and emergency room utilization among adults with type 2 diabetes (T2DM) is partially driven by cost-related non-adherence. Objective: To test the impact of the Diabetes Health Plan (DHP), a diabetes-specific health plan incorporating value-based insurance design principles on healthcare utilization among low-income adults with T2DM. Design: To examine the impact of the DHP on healthcare utilization, we employed a difference-in-differences (DID) study design with a propensity-matched comparison group. We modeled count and dichotomous outcomes using Poisson and logit models, respectively. Participants: Cohort of adults (18–64) with T2DM, with an annual household income <$ 30,000, and who were continuously enrolled in an employer-sponsored UnitedHealthcare plan for at least 2 years between 2009 and 2014. Interventions: The DHP reduces or eliminates out-of-pocket costs for disease management visits, diabetes-related medicines, and diabetes self-monitoring supplies. The DHP also provides access to diabetes-specific telephone case management as well as other online resources. Main Measures: Number of disease management visits (N = 1732), any emergency room utilization (N = 1758), and any hospitalization (N = 1733), within the year. Key Results: DID models predicting disease management visits suggested that DHP-exposed beneficiaries had 1.7 fewer in-person disease management visits per year (− 1.70 [95% CI: − 2.19, − 1.20], p < 0.001), on average, than comparison beneficiaries. Models for emergency room (0.00 [95% CI: − 0.06, 0.06], p = 0.966) and hospital utilization (− 0.03 [95% CI: − 0.08, − 0.01], p = 0.164) did not demonstrate statistically significant changes associated with DHP exposure. Conclusions: While no relationship between DHP exposure and high-cost utilization was observed in the short term, fewer in-person disease management visits were observed. Future studies are needed to determine the clinical implications of these findings.


  • Open Access

    An Effectiveness Study of a Primary Care-embedded Clinical Pharmacist-Led Intervention Among Patients With Diabetes and Medicaid Coverage

    by Kimberly Danae Cauley Narain, Chi-Hong Tseng, Douglas Bell, Amanda Do, Rob Follett, O. Kenrik Duru, Gerardo Moreno, Carol Mangione

    Objective: Examine the impact of a primary care-embedded clinical pharmacist-led intervention (UCMyRx) on hemoglobin A1C and blood pressure control, relative to usual care, among patients with Type 2 diabetes (TD2) and Medicaid, in a large healthcare system. Methods: We used data extracted from the Electronic Health Records system and a Difference-In-Differences study design with a 2:1 propensity-matched comparison group to evaluate the impact of UCMyRx on HbA1c and systolic blood pressure among patients with TD2 and Medicaid, relative to usual care. Results: Having at least one UCMyRx clinical pharmacist visit was associated with a significant reduction in HbA1c; (−.27%, P-value= .03) but no impact on SBP. We do not find differential UCMyRx effects on HbA1c or SBP among the subpopulations with baseline HbA1C ≥9% or SBP ≥150 mmHg, respectively. In Charlson Comorbidity Index (CCI)-stratified analyses we found stronger UCMyRx effects on HbA1C (−.47%, P-value< .02) among the CCI tercile with the lowest comorbidity score (CC1 ≤ 5). Significant UCMyRx effects are only observed among the subpopulation of Medicaid beneficiaries without Medicare (−.35%, P-value= .02). Conclusions: The UCMyRx intervention is a useful strategy for improving HbA1c control among patients with TD2 and Medicaid.


  • Open Access

    Exploring the relationship between self-employment and women’s cardiovascular health

    by Sedina Dzodzomenyo, Kimberly Danae Cauley Narain

    Background: Compared with wage and salary work, self-employment has been linked to more favorable cardiovascular health outcomes within the general population. Women comprise a significant proportion of the self-employed workforce and are disproportionately affected by cardiovascular disease. Self-employed women represent a unique population in that their cardiovascular health outcomes may be related to gender-specific advantages of non-traditional employment. To date, no studies have comprehensively explored the association between self-employment and risk factors for cardiovascular disease among women. Methods: We conducted a weighted cross-sectional analysis using data from the University of Michigan Health and Retirement Study (HRS). Our study sample consisted of 4624 working women (employed for wages and self-employed) enrolled in the 2016 HRS cohort. Multivariable linear and logistic regression were used to examine the relationship between self-employment and several self-reported physical and mental health risk factors for cardiovascular disease, controlling for healthcare access. Results: Among working women, self-employment was associated with a 34% decrease in the odds of reporting obesity, a 43% decrease in the odds of reporting hypertension, a 30% decrease in the odds of reporting diabetes, and a 68% increase in the odds of reporting participation in at least twice-weekly physical activity (p < 0.05). BMI for self-employed women was on average 1.79 units lower than it was for women working for wages (p < 0.01). Conclusions: Employment structure may have important implications for cardiovascular health among women, and future studies should explore the causal relationship between self-employment and cardiovascular health outcomes in this population. Trial Registration: Not applicable.


  • Open Access

    Evidence for the Role of State-Level Economic Policy in HIV Risk Reduction: State Earned Income Tax Credit Generosity and HIV Risk Behavior Among Single Mothers

    by Kimberly Danae Cauley Narain, Nina Harawa

    We investigated the impact of State-level Earned Income Tax Credit (SEITC) generosity on HIV risk behavior among single mothers with low education. We merged individual-level data from the Behavioral Risk Factor Surveillance System (2002–2018) with state-level data from the University of Kentucky Center for Poverty Research and conducted a multi-state, multi-year difference-in-differences (DID) analysis. We found that a refundable SEITC ≥ 10% of the Federal Earned Income Tax Credit was associated with 21% relative risk reduction in reporting any high-risk behavior for HIV in the last year, relative to no SEITC. We also found that a 10-percentage point increase in SEITC generosity was associated with 38% relative risk reduction in reporting any high-risk HIV behavior in the last year. SEITC policy may be an important strategy to reduce the burden of HIV infections among women with low socioeconomic status, particularly single mothers.